טוען...
NIMG-67. ADVANCED PERFUSION AND DIFFUSION MR IMAGING IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR TREATING FIELDS (TTFIELDS) AS FIRST-LINE THERAPY
BACKGROUND: Tumor treating fields (TTFields) is an antimitotic and FDA-approved first and second-line therapy for patients with glioblastoma. In recurrent glioblastoma, it has been reported that imaging response to TTFields is generally delayed (~158 days), where 44% of responders developed initial...
שמור ב:
| הוצא לאור ב: | Neuro Oncol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692961/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.640 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|